Navigation Links
Heska Announces First Installation of New Blood Gas & Electrolyte Analyzer

LOVELAND, Colo., May 19 /PRNewswire-FirstCall/ -- Heska Corporation (Nasdaq: HSKA) ("Heska" or the "Company"), a leading provider of veterinary diagnostic and specialty products, announced today the first installations of the Company's new VitalPath™ Blood Gas & Electrolyte Analyzer (the "VitalPath").


Veterinary customers receiving these analyzers have invested in a major advancement to in-clinic diagnostics.  The VitalPath analyzer delivers accurate results in just 50 seconds for blood gases, electrolytes, and hematocrit, as well as 27 additional calculated parameters.  Requiring just under 70 microliters of sample, the VitalPath can be customized to suit the needs of any clinic.

"We are very pleased to offer the VitalPath analyzer as an essential part of the veterinary team's in-house laboratory," says Michael J. McGinley, President and Chief Operating Officer of Heska Corporation. "Our customers have the highest standards for companion animal care and in emergencies, they depend on fast, accurate results to make immediate treatment decisions.  We are proud to address this important need with the latest edition to our advanced line-up of diagnostic blood analyzers."

About Heska

Heska Corporation (Nasdaq: HSKA) sells advanced veterinary diagnostic and other specialty veterinary products.  Heska's state-of-the-art offerings to its customers include diagnostic instruments and supplies as well as single use, point-of-care tests, pharmaceuticals and vaccines.  The company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians.  For further information on Heska and its products, visit the company's website at

Forward-Looking Statements

This announcement contains forward-looking statements regarding Heska's future financial and operating results.  These statements are based on current expectations and are subject to a number of risks and uncertainties.  Investors should note that there is an inherent risk in using past results, including trends, to predict future outcomes.  In addition, factors that could affect the business and financial results of Heska generally include the following: uncertainties related to the performance of products as anticipated over time; uncertainties related to the timely and level of market acceptance of new products; risks related to Heska's reliance on third-party suppliers, which is significant; risks related to the commercialization of new products; competition; risks related to Heska's ability to maintain its listing on the NASDAQ Capital Market; risks related to Heska's ability to market and sell its products in an economically viable manner; uncertainties related to the impact of transfer restrictions on Heska's stock, which were approved by Heska stockholders at Heska's Annual Meeting of Stockholders on May 4, 2010; and the risks set forth in Heska's filings and future filings with the Securities and Exchange Commission, including those set forth in Heska's Quarterly Report on Form 10-Q for the quarter ended March 31, 2010.

SOURCE Heska Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Heska to Present at SunTrust Robinson Humphrey 1st Annual Veterinary Conference
2. Webcast Alert: Heska Announces Fourth Quarter and Year-End 2009 Earnings Conference Call Webcast
3. Heska Announces Extension of Credit Agreement With Wells Fargo
4. Heska Announces Supply Agreement With Roche Diagnostics
5. Heska Announces Launch of New Website
6. Heska Announces Q309 Results
7. Winner Medical Group Inc. Announces Exercise of Over-Allotment Option Bringing Aggregate Net Proceeds of the Public Offering to $8.8 Million
8. Stryker Announces Resolution of Two FDA Warning Letters
9. Medical Product Outsourcing Magazine Announces the First Annual CardioTec Conference
10. Thoratec Announces Early Termination of HSR Waiting Period for the Sale of ITC to Danaher Corporation
11. China Sky One Medical Announces First Quarter 2010 Results
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 3D bioprinting ... 2022, according to a new report by Grand View Research ... Disease (CKD) which demands kidney transplantation is expected to boost ... effective substitute for organ transplantation. --> 3D bioprinting ... 2022, according to a new report by Grand View Research ...
(Date:11/26/2015)... 2015 ) ... "2016 Future Horizons and Growth Strategies in ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> ) has announced ... Horizons and Growth Strategies in the French ...
(Date:11/26/2015)... , November 26, 2015 ... of the "2016 Future Horizons and ... Abuse Testing Market: Supplier Shares, Country Segment ... to their offering. --> ... "2016 Future Horizons and Growth Strategies ...
Breaking Medicine Technology:
(Date:11/26/2015)... Omaha, NE (PRWEB) , ... November 26, 2015 , ... ... careers searched by healthcare professionals and offered by healthcare staffing agency Aureus Medical ... top during the month of October 2015 among those searching for healthcare jobs through ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel ... self-animating trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack comes with ... work with any font, giving users limitless opportunities to stylize and create designs ...
(Date:11/25/2015)... ... November 25, 2015 , ... Additional breast cancers found ... mammography, according to a study published online in the journal Radiology. Researchers said ... may necessitate a change in treatment. , Breast MRI is the most sensitive ...
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in the ... several models of traditional and far-infrared saunas. , For traditional saunas, Finnleo ... most traditional Finnish sauna wood, and Finnleo uses only European Grade A Nordic White ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director ... about hair loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for ... and fuller hair, without the need for surgery, prescription pills, or topical foams. ...
Breaking Medicine News(10 mins):